Abstract: A method of treating a viral respiratory infection, such as infection by at least one of a SARS virus, a coronavirus or SARS-CoV-2, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent which includes a beta thymosin peptide with amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof.

Abstract: Inflammation or damage associated with myocardial events is treated or prevented by administration of an angiogenesis-inducing, anti-inflammatory peptide such as Thymosin ?4, an isoform of Thymosin ?4 or oxidized Thymosin ?4.

Abstract: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject in need of such treatment an effective amount of a composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in the tissue.

Abstract: Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin ?4, an isoform of Thymosin ?4, oxidized Thymosin ?4, or T?4 sulfoxide.

Abstract: A method of conserving and/or preparing an organ or tissue for transplant for a subject, includes administering to a subject, organ or tissue in need of such treatment an effective amount of a composition including a polypeptide agent including thymosin beta 4 (TB4), an isoform, analogue or derivative of TB4 having biological activity of TB4, an N-terminal variant of TB4 having biological activity of TB4, a C-terminal variant of TB4 having biological activity of TB4, LKKTET or a conservative variant thereof, LKKTNT or a conservative variant thereof, KLKKTET or a conservative variant thereof, LKKTETQ or a conservative variant thereof, TB4 sulfoxide, TB4ala, TB9, TB10, TB11, TB12, TB13, TB14, TB15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, adsevertin, propomyosin, fincilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, ?-actinin or acumentin, or a stimulating agent that stimulates production of a polypeptide agent as described above, or a conservative variant thereof, in the or

Abstract: A pharmaceutical, ophthalmic or cosmetic combination or method utilizes a peptide agent include amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, and further utilizes a quaternary ammonium salt, wherein the agent and the salt can be administered to a subject separately or together.